Azitra Inc (AZTR) - Total Assets
Based on the latest financial reports, Azitra Inc (AZTR) holds total assets worth $5.03 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Azitra Inc net assets for net asset value and shareholders' equity analysis.
Azitra Inc - Total Assets Trend (2021–2025)
This chart illustrates how Azitra Inc's total assets have evolved over time, based on quarterly financial data.
Azitra Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Azitra Inc's total assets of $5.03 Million consist of 60.1% current assets and 39.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 41.2% |
| Accounts Receivable | $141.29K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $316.67 Million | 6.3% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2021–2025)
This chart illustrates how Azitra Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Azitra Inc worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Azitra Inc's current assets represent 60.1% of total assets in 2025, a decrease from 83.2% in 2021.
- Cash Position: Cash and equivalents constituted 41.2% of total assets in 2025, down from 78.9% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 6.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 6.3% of total assets.
Azitra Inc Competitors by Total Assets
Key competitors of Azitra Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Allakos Inc
NASDAQ:ALLK
|
USA | $59.55 Million |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
Arcutis Biotherapeutics Inc
NASDAQ:ARQT
|
USA | $460.00 Million |
|
Youcare Pharmaceutical Group Co. Ltd. A
SHG:688658
|
China | CN¥5.19 Billion |
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
USA | $424.43 Million |
|
Chengdu Kanghua Biological Products
SHE:300841
|
China | CN¥3.94 Billion |
Azitra Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.83 | 3.80 | 1.86 |
| Quick Ratio | 2.83 | 3.80 | 1.86 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $1.95 Million | $3.85 Million | $1.91 Million |
Azitra Inc - Advanced Valuation Insights
This section examines the relationship between Azitra Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 68190.8% |
| Total Assets | $5.03 Billion |
| Market Capitalization | $3.19 Million USD |
Valuation Analysis
Below Book Valuation: The market values Azitra Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Azitra Inc's assets grew by 68190.8% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Azitra Inc (2021–2025)
The table below shows the annual total assets of Azitra Inc from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $5.03 Billion | +68190.82% |
| 2024-12-31 | $7.36 Million | +43.85% |
| 2023-12-31 | $5.12 Million | -28.63% |
| 2022-12-31 | $7.17 Million | -29.74% |
| 2021-12-31 | $10.20 Million | -- |
About Azitra Inc
Azitra, Inc., an early-stage clinical biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and topical live biotherapeutic products to treat skin diseases in the United States. The company develops ATR-04, a genetically modified strain of S. epidermidis that is in a Phase 1/2 clinical trial for treating the papulopustular rash experienced by cancer pat… Read more